Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report) Director Yusheng Han bought 250,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00. Following the completion of the purchase, the director directly owned 18,379,186 shares of the company’s stock, valued at $147,033,488. This represents a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Yusheng Han also recently made the following trade(s):
- On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, with a total value of $199,200.00.
- On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $7.50 per share, with a total value of $44,925.00.
- On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $7.45 per share, for a total transaction of $779,642.50.
- On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.00 per share, for a total transaction of $999,990.00.
- On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00.
- On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was bought at an average price of $8.74 per share, with a total value of $216,402.40.
Burning Rock Biotech Stock Up 9.6%
BNR opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $12.57 and its 200 day simple moving average is $20.04. The stock has a market cap of $103.31 million, a PE ratio of -11.98 and a beta of 1.32.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on BNR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech has a consensus rating of “Sell”.
Check Out Our Latest Research Report on BNR
Institutional Trading of Burning Rock Biotech
A number of institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares during the last quarter. Marshall Wace LLP purchased a new stake in Burning Rock Biotech in the 4th quarter worth approximately $220,000. Crcm LP lifted its holdings in Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after buying an additional 269,851 shares during the period. Finally, Prospera Financial Services Inc grew its position in shares of Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the last quarter. 30.03% of the stock is currently owned by hedge funds and other institutional investors.
About Burning Rock Biotech
Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.
Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.
Read More
- Five stocks we like better than Burning Rock Biotech
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
